Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.
Nicholls
John M
JM
Aschenbrenner
Laura M
LM
Paulson
James C
JC
Campbell
Erin R
ER
Malakhov
Michael P
MP
Wurtman
David F
DF
Yu
Mang
M
Fang
Fang
F
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001422:Bacterial Adhesion; D004196:Disease Outbreaks / Q000517:prevention & control*; D006801:Humans; D007251:Influenza, Human / Q000517:prevention & control*; D037102:Lectins / Q000378:metabolism; D009439:Neuraminidase / Q000494:pharmacology / Q000627:therapeutic use*; D011008:Pneumococcal Infections; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D020545:Respiratory Mucosa / Q000737:chemistry; D013296:Streptococcus pneumoniae / Q000502:physiology
D000998:Antiviral Agents; D037102:Lectins; D011994:Recombinant Proteins; D009439:Neuraminidase